Compare · AVTR vs OMIC
AVTR vs OMIC
Side-by-side comparison of Avantor Inc. (AVTR) and Singular Genomics Systems Inc. (OMIC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and OMIC operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- AVTR carries a market cap of $10.53B.
- AVTR has hit the wire 8 times in the past 4 weeks while OMIC has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 5 for OMIC).
- Company
- Avantor Inc.
- Singular Genomics Systems Inc.
- Price
- -
- -
- Market cap
- $10.53B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 5
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Singular Genomics Systems Inc.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
Latest AVTR
- EVP, Chief Operating Officer Blenn Mary covered exercise/tax liability with 2,900 shares, decreasing direct ownership by 1% to 250,484 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief Legal & Compliance Sokenu Claudius was granted 62,305 shares, increasing direct ownership by 25% to 313,533 units (SEC Form 4)
- EVP, Chief HR Officer Hankamer Brittany was granted 46,728 shares, increasing direct ownership by 19% to 295,592 units (SEC Form 4)
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by Avantor Inc.
- SEC Form 8-K filed by Avantor Inc.
- Avantor® Reports Third Quarter 2026 Results
- Avantor appoints new Chief Information Officer
- Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter
- Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
Latest OMIC
- Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)
- Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.
- Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Glezer Eli N. returned 155,583 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operating Officer Ghai Jyotsna returned 3,283 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Ryan Jason
- Director Pellini Michael J returned 351,222 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Mardis Elaine R